{"generic":"Perflutren Lipid Microsphere","drugs":["Definity","Perflutren Lipid Microsphere"],"mono":{"0":{"id":"926617-s-0","title":"Generic Names","mono":"Perflutren Lipid Microsphere"},"1":{"id":"926617-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926617-s-1-4","title":"Adult Dosing","mono":"<ul><li>Perflutren in lipid microspheres designates the intact formulation of octafluoropropane in lipid microspheres.  Another formulation of octafluoropropane is available, consisting of octafluoropropane in albumin microspheres (Optison(TM)). It is recognized by the FDA as a molecular entity different from perflutren in lipid microspheres.  For further information, consult the perflutren in albumin microspheres monograph.<\/li><li><b>Echocardiography; Adjunct:<\/b> bolus, 10 microliters\/kg within 30 to 60 seconds of activation, followed by a 10 mL saline flush. To prolong contrast enhancement, a second 10 microliters\/kg dose, followed by a second 10 mL saline flush may be administered 30 minutes after the first injection<\/li><li><b>Echocardiography; Adjunct:<\/b> infusion, 1.3 mL perflutren lipid microsphere added to 50 mL of preservative-free saline and initiate infusion at 4 mL\/minute. Titrate to achieve optimal image enhancement; do not exceed 10 mL\/minute<\/li><\/ul>"},"3":{"id":"926617-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Echocardiography; Adjunct<br\/>"}}},"2":{"id":"926617-s-2","title":"Black Box Warning","mono":"<b>Injection (Suspension)<\/b><br\/>Serious or fatal cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren lipid microsphere administration. Most serious reactions occur within 30 minutes of administration. Monitor all patients for the presence of any condition that precludes perflutren lipid microsphere administration and always have resuscitation equipment and trained personnel readily available.<br\/>"},"3":{"id":"926617-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926617-s-3-9","title":"Contraindications","mono":"<ul><li>cardiac shunts, right-to-left, bi-directional, or transient right-to-left; risk of microvascular occlusion and ischemia as phospholipid encapsulated microspheres can bypass the pulmonary particle-filtering mechanisms and directly enter the arterial circulation<\/li><li>hypersensitivity to perflutren<\/li><li>intra-arterial administration<\/li><\/ul>"},{"id":"926617-s-3-10","title":"Precautions","mono":"<ul><li>cardiopulmonary reactions, serious (eg, cardiac or respiratory arrest, symptomatic arrhythmias, shock, syncope, convulsions, hypotension, respiratory distress, or loss of consciousness), including fatalities, have occurred during or shortly following (usually within 30 minutes) perflutren administration; monitoring recommended<\/li><li>cardiopulmonary conditions, unstable (eg, acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias); increased risk of serious and potentially fatal cardiopulmonary reactions; monitoring recommended<\/li><li>anaphylactoid reactions, serious (eg, shock, hypersensitivity, bronchospasm, upper airway swelling, and angioedema), have been reported during or shortly following administration; monitoring recommended<\/li><li>high ultrasound mechanical index; risk of ventricular arrhythmias as a result of microsphere cavitation or rupture<\/li><li>QT interval prolongation has been reported<\/li><\/ul>"},{"id":"926617-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"926617-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"926617-s-4","title":"Drug Interactions","sub":[{"id":"926617-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"926617-s-4-14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"926617-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (0.8%)<\/li><li><b>Dermatologic:<\/b>Flushing (1.1%), Injection site reaction (0.6%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (1%)<\/li><li><b>Musculoskeletal:<\/b>Backache<\/li><li><b>Neurologic:<\/b>Dizziness (0.6%), Headache (2.3%)<\/li><li><b>Renal:<\/b>Renal pain<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Cardiac dysrhythmia, Prolonged QT interval (29%), Shock<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction<\/li><li><b>Neurologic:<\/b>Loss of consciousness<\/li><li><b>Respiratory:<\/b>Respiratory arrest, Respiratory distress<\/li><\/ul>"},"6":{"id":"926617-s-6","title":"Drug Name Info","sub":{"0":{"id":"926617-s-6-17","title":"US Trade Names","mono":"Definity<br\/>"},"2":{"id":"926617-s-6-19","title":"Class","mono":"Radiological Non-Ionic Contrast Media<br\/>"},"3":{"id":"926617-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"926617-s-7","title":"Mechanism Of Action","mono":"Perflutren is an intravenous ultrasound contrast agent composed of octafluoropropane (perfluoropropane) gas encapsulated in lipid microspheres. When given intravenously, the acoustic properties of the octafluoropropane-filled lipid microspheres enable improved left-ventricular cavity enhancement and delineation of endocardial borders during echocardiography. The acoustic impedance of perflutren is lower than that of blood, which is associated with enhancement of the intrinsic backscatter of blood; this can be visualized as a brighter blood pool compared to darker myocardium.<br\/>"},"8":{"id":"926617-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"926617-s-8-24","title":"Distribution","mono":"Protein binding: minimal <br\/>"},"2":{"id":"926617-s-8-25","title":"Metabolism","mono":"Hepatic: speculated <br\/>"},"3":{"id":"926617-s-8-26","title":"Excretion","mono":"Lungs <br\/>"},"4":{"id":"926617-s-8-27","title":"Elimination Half Life","mono":"1.3 minutes <br\/>"}}},"9":{"id":"926617-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>prior to administration, activate by shaking for a full 45 seconds in an apparatus (Vialmix(R)) provided by the manufacturer<\/li><li>activated perflutren in lipid microspheres is a milky white suspension and may be used immediately after activation<\/li><li>resuspend the product by 10 seconds of hand agitation (through inverting the vial prior to product withdrawal from the vial) if not used within 5 minutes of activation<\/li><li>activated perflutren in lipid microspheres can be used for up to 12 hours from time of Vialmix(R), but only after the microspheres are resuspended by hand agitation<\/li><li>do not inject air into the vial<\/li><li>withdraw product from the middle of the vial with the Intellipin(R) dispensing pin or with a 18- or 20- gauge syringe needle<\/li><li>use product immediately upon withdrawal from vial; do not let the product stand in the syringe<\/li><li>vials are for SINGLE-USE ONLY as they contain no bacterial preservative.<\/li><li>bolus injection, use a 18- to 20-gauge needle via forearm vein. <\/li><li>continuous infusion, 1.3 mL activated perflutren should be diluted in 50 mL preservative-free saline; initiate infuse at 4 mL\/min, titrate as needed not to exceed 10 mL\/min.<\/li><\/ul>"},"10":{"id":"926617-s-10","title":"Monitoring","mono":"<ul><li>high quality left-ventricular contrast opacification and delineation of the left ventricular endocardial border is indicative of efficacy<\/li><li>acute cardiopulmonary reactions, including fatal cardiac or respiratory arrest, shock, symptomatic arrhythmias, and convulsions; generally occur within 30 minutes of administration; may be more likely to occur in those with unstable cardiopulmonary conditions<\/li><\/ul>"},"13":{"id":"926617-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause headache, back and renal pain, flushing, and nausea.<\/li><li>Instruct patient to report signs\/symptoms of arrhythmia, tachycardia, hypotension, or cardiac or respiratory arrest.<\/li><\/ul>"}}}